Alcon, Inc. (ALC)
| Market Cap | 41.78B |
| Revenue (ttm) | 8.08B |
| Net Income (ttm) | 332.00M |
| Shares Out | 490.10M |
| EPS (ttm) | 0.67 |
| PE Ratio | 127.41 |
| Forward PE | 33.33 |
| Dividend | $0.20 (0.23%) |
| Ex-Dividend Date | n/a |
| Volume | 540,640 |
| Open | 84.50 |
| Previous Close | 83.36 |
| Day's Range | 83.66 - 85.26 |
| 52-Week Range | 62.63 - 87.49 |
| Beta | 0.49 |
| Analysts | Buy |
| Price Target | 85.83 (+0.7%) |
| Earnings Date | Nov 9, 2021 |
About ALC
Alcon, Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR sur...
Financial Performance
Financial StatementsAnalyst Forecast
According to 25 analysts, the average rating for Alcon stock is "Buy." The 12-month stock price forecast is 85.83, which is an increase of 0.69% from the latest price.
News
Alcon (ALC) Surgical Arm Grows Amid Global Trade Disruption
Segment wise, within Alcon's (ALC) Surgical arm, the portfolio of advanced technology intraocular lenses is driving increased penetration rates of ATIOLs.
Alcon (ALC) Q3 Earnings Beat Estimates, Margin Improves
Alcon (ALC) records year-over-year growth across all sales categories in Surgical and Vision Care in Q3.
Alcon Big Winner in 2019 Divorce From Novartis
Since being spun off into a separate company in April 2019, Alcon Inc. ( ALC , Financial) shares have thrived while the stock of its former parent, Novartis AG ( NVS , Financial), has languished.
Alcon Reports Third Quarter 2021 Results
GENEVA--(BUSINESS WIRE)--Alcon Reports Third Quarter 2021 Results
Alcon Unveils Latest Evolution of Cataract Integration and Connectivity at AAO 2021
FORT WORTH, Texas--(BUSINESS WIRE)--Alcon Unveils Latest Evolution of Cataract Integration and Connectivity at AAO 2021
Alcon to Acquire Ivantis, Inc. and its Hydrus Microstent for Surgical Glaucoma, Strengthening Global Ophthalmology Po...
GENEVA--(BUSINESS WIRE)--Alcon to Acquire Ivantis, Inc. and its Hydrus Microstent for Surgical Glaucoma, Strengthening Global Ophthalmology Portfolio
Alcon #Academy21 Program to Showcase TOTAL30, Other Innovations that Meet Critical Patient and Practice Needs
FORT WORTH, Texas--(BUSINESS WIRE)--Alcon #Academy21 Program to Showcase TOTAL30, Other Innovations that Meet Critical Patient and Practice Needs
Alcon Celebrates World Sight Day 2021 in Communities Worldwide with Programs for Improved Access to Eye Care
GENEVA--(BUSINESS WIRE)--Alcon Celebrates World Sight Day 2021 in Communities Worldwide with Programs for Improved Access to Eye Care
Alcon's (ALC) Robust Product Line, Market Rebound Aid Growth
In Presbyopia-correcting Intraocular Lens (PCIOLs), Alcon (ALC) currently leads the market with over 55% of global share and over 80% share in the United States.
Alcon Honored with FutureEdge 50 Award
FORT WORTH, Texas--(BUSINESS WIRE)--Alcon Honored with FutureEdge 50 Award
Here's Why You Should Add Alcon Stock (ALC) to Your Portfolio
Investors continue to be optimistic about Alcon (ALC) backed by robust second-quarter performance and raised 2021 outlook.
4 Stocks to Keep a Watch on Amid Growing Optical Care Demand
Stocks like Alcon (ALC), National Vision (EYE), The Cooper Companies (COO) and EyePoint Pharmaceuticals (EYPT) are gaining momentum amid rising optical care demand.
Alcon reports strong second-quarter results and positive long term outlook
David Endicott, CEO at Alcon, discusses second-quarter earnings.
Alcon (ALC) Q2 Earnings Top Estimates, 2021 Guidance Up
Alcon (ALC) records the highest sales in the second quarter of 2021 since its spin-off.
Investors Cheer Alcon's Updated Annual Guidance
Alcon AG (NYSE: ALC) reported second-quarter FY21 sales of $2.1 billion, +75% Y/Y on a reported basis and +69% on a constant currency basis, beating the consensus of $1.96 billion. All categories benefi...
Alcon Reports Second Quarter 2021 Results
GENEVA--(BUSINESS WIRE)--Alcon Reports Second Quarter 2021 Results
Alcon (ALC) to Report Q2 Earnings: What's in the Cards?
Continued strength in the Surgical segment and new launches under Vision Care segment are likely to have driven growth in the second quarter for Alcon (ALC).
Alcon to Launch TOTAL30 as the First-and-Only Monthly Replacement, Water Gradient Contact Lens
GENEVA--(BUSINESS WIRE)--Alcon to Launch TOTAL30 as the First-and-Only Monthly Replacement, Water Gradient Contact Lens
3 Medical Instruments Stocks Countering Industry Headwinds
The Zacks Medical - Instruments industry is growing on base business recovery. ISRG, IDXX and ALC are set to gain the most.
Alcon Reinforces Strength of Industry-Leading Ophthalmology Portfolio with Largest Surgical Device Scientific Presenc...
FORT WORTH, Texas--(BUSINESS WIRE)--Alcon Reinforces Strength of Industry-Leading Ophthalmology Portfolio with Largest Surgical Device Scientific Presence at ASCRS 2021
Reposition your portfolio for dividend yields, says Ariel's Bhansali
Rupal Bhansali, Ariel International Fund & Ariel Global Fund portfolio manager, discusses her approach to investing right now as well as her top picks for the second half of the year.
Alcon Announces Executive Committee Changes
GENEVA--(BUSINESS WIRE)--Alcon Announces Executive Committee Changes
Alcon to Showcase Vision Care Innovation, Including Clinical Data for its Forthcoming Reusable Monthly Lens TOTAL30, ...
GENEVA--(BUSINESS WIRE)--Alcon to Showcase Vision Care Innovation, Including Clinical Data for its Forthcoming Reusable Monthly Lens TOTAL30, at BCLA 2021
Alcon Reports First Quarter 2021 Results
GENEVA--(BUSINESS WIRE)--Alcon Reports First Quarter 2021 Results
Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
GENEVA--(BUSINESS WIRE)--Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza